Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Investigating Dupilumab's Effect in Asthma by Genotype (IDEA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03694158
Recruitment Status : Recruiting
First Posted : October 3, 2018
Last Update Posted : May 30, 2023
National Institute of Allergy and Infectious Diseases (NIAID)
Regeneron Pharmaceuticals
HealthBeacon Plc
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Wanda Phipatanakul, Boston Children's Hospital

Brief Summary:
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma exacerbations.

Condition or disease Intervention/treatment Phase
Asthma Drug: Dupilumab Other: Placebo Phase 4

Detailed Description:

This is a double-blind, randomized, placebo-controlled parallel-group phase 4 clinical trial.

Patients will be genotyped and categorized as those with: 1) the wild type allele (Q576/Q576), 2) heterozygous allele (Q576/R576), or 3) homozygous mutant allele (R576/R576); the genotype associated with more severe disease.

After a run-in period of 2-12 weeks to determine asthma control, subjects who fulfill all inclusion/exclusion criteria will be randomized to receive either subcutaneous Dupilumab or placebo (1:1 randomization allocation ratio).

This study addresses fundamental mechanisms by which the IL-4Rα-R576 variant drives the TH2/TH17 disease endotype and the influence of this variant on response to Dupilumab therapy. It brings together individuals with deep clinical and scientific expertise in allergic diseases, including epidemiology, genetics, inflammation, and tolerance mechanisms to investigate, in a coordinated strategy, the hypothesis that the IL-4Rα-R576 variant drives TH2/TH17 cell inflammation by subverting allergen-specific iTreg cells into TH17 cells. Asthmatics bearing this endotype will be particularly likely to favorably respond to Dupilumab therapy by virtue of its prevention of iTreg cell reprogramming into TH17-like cells, potentially leading to their long-term stability and potential for sustained immune tolerance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a genotype stratified, double-blind, randomized, placebo-controlled, parallel-group, phase IV clinical trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double blind, placebo controlled.
Primary Purpose: Treatment
Official Title: Effect of IL-4RαR576 Polymorphism on Response to Dupilumab in Asthma, a Genotype-stratified, Randomized, Placebo- Controlled Trial
Actual Study Start Date : September 8, 2021
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : March 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
Drug Information available for: Dupilumab

Arm Intervention/treatment
Experimental: Treatment group
Dupilumab (Dupixent®) administered subcutaneously every two weeks. An initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week.
Drug: Dupilumab
anti-IL4 receptor antagonist
Other Name: Dupixent®

Placebo Comparator: Placebo group
Placebo (preparation, administration, packaging, and labeling all equivalent to the treatment) administered subcutaneously every two weeks.
Other: Placebo
Placebo for Dupilumab (packaged/administered the same as the active drug)

Primary Outcome Measures :
  1. The rate of asthma exacerbations [ Time Frame: 48 week treatment period ]
    An exacerbation is an asthma attack for which a clinician prescribed a course of systemic steroids, whether or not the patient took the steroids.

Secondary Outcome Measures :
  1. Change in pre-bronchodilator lung function [ Time Frame: average of week 4,12, 24,36 and 48 week ]
    the change in pre-bronchodilator FEV1% predicted from baseline

  2. Change in CASI score [ Time Frame: average of 4,12, 24, 36, and 48 week ]
    The change in CASI score from baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Ages 12 years and older
  2. Ability to provide informed consent
  3. Ability to perform pulmonary function tests
  4. Female participants of childbearing potential must have a negative urine pregnancy test upon study entry
  5. Female participants with reproductive potential must agree to use FDA-approved methods of birth control for the duration of the study2
  6. Participant-reported physician or licensed medical practitioner diagnosis of asthma
  7. Treatment with medium to high dose ICS (400 mcg to maximum of 2000 mcg per day of fluticasone propionate or equivalent) for at least 3 months with a stable dose ≥1 month prior to screening OR used a biologic medication for asthma within the past 8 weeks
  8. History of asthma exacerbation in the past year

An exacerbation is an asthma attack for which a clinician prescribed a course of systemic (oral, IV, IM) steroids whether or not the patient took the steroids OR An increase of >50% of baseline inhaled corticosteroid dose for ≥3 days OR An unscheduled visit for acute asthma attack (licensed medical practitioner/nurse office, urgent care intervention, emergency department, or hospitalization)

Exclusion Criteria:

  1. Chronic lung disease other than asthma, which may impair lung function
  2. Current smoker or cessation of smoking ≤6 months prior to Visit 0 screening
  3. Current use of any electronic (e) "vaping" device (e.g., e-cigarette, e-cig, mod, vape pen, JUUL, e-cigar, e-hookah, e-pipe, vape pods) or cessation ≤ 6 months prior to screening
  4. Pregnant or breast feeding
  5. Any other condition or abnormality that, in the opinion of the Principal Investigator, would compromise the safety of the patient or quality of data
  6. Evidence that the participant or family may be unreliable or poorly adherent to their asthma treatment or study procedures
  7. Planning to relocate away from the clinical center area before study completion
  8. Currently participating in an investigational drug trial or participated in one within 30 days before screening
  9. Currently being treated with immunosuppressive/immunomodulatory or other investigational agents or biologics for conditions other than asthma, or used a biologic for a non-asthma indication within the past 6 months
  10. History of respiratory illness requiring antibiotics or systemic corticosteroids, including asthma exacerbations, within the past 4 weeks (evaluated at time of screening visit)
  11. History of alcohol or illicit substance abuse within 6 months of screening
  12. Neutropenia (<1,000/mm3) or thrombocytopenia (<100,000/mm3) or hemoglobin < 100 g/L (10 g/dL) or blood eosinophils > 1500/mm3 at screening
  13. Administration of a live vaccine within 4 weeks of screening
  14. Currently receiving allergen immunotherapy (food or aeroallergen) other than an established maintenance regimen implemented continuously for a minimum of 2 months. Individuals receiving aeroallergen immunotherapy must be willing to stay on it for the duration of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03694158

Layout table for location contacts
Contact: Wanda Phipatanakul, MD, MS 857-218-5336
Contact: Claudina Luna

Layout table for location information
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Claudina Luna, MD. MPH.    857-218-5336   
Principal Investigator: Wanda Phipatanakul, MD.MS.         
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Angeles Cinelli   
Principal Investigator: Eliot Israel, MD         
United States, Michigan
Henry Ford Health System Recruiting
Detroit, Michigan, United States, 48202
Contact: Sherae Hereford, RN    313-207-2453   
Principal Investigator: Haejin Kim, MD.         
United States, New Jersey
Atlantic Health System Recruiting
Cedar Knolls, New Jersey, United States, 07927
Contact: Juliana Colecchia    908-934-0555 ext 78625   
Principal Investigator: John Oppenheimer, MD         
United States, New York
Montefiore Einstein Clinical Research Center Recruiting
Bronx, New York, United States, 10467
Contact: Samuel Green    718-920-7777   
Contact: Sunit Jariwala, MD    609-937-1023   
Principal Investigator: Sunit Jariwala, MD.         
United States, Ohio
MetroHealth System Recruiting
Cleveland, Ohio, United States, 44109
Contact: David Kaelber, MD.PHD. MPH.    216-780-3722   
Contact: Kimberly Schach    216-778-7992   
Principal Investigator: David Kaelber, MD.PHD.MPH.         
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Elizabeth Beothy    215-549-5023   
Contact: Audreesh Banerjee, MD    215-549-5023   
Principal Investigator: Audreesh Banerjee, MD         
Sponsors and Collaborators
Boston Children's Hospital
National Institute of Allergy and Infectious Diseases (NIAID)
Regeneron Pharmaceuticals
HealthBeacon Plc
Merck Sharp & Dohme LLC
Layout table for investigator information
Principal Investigator: Wanda Phipatanakul Boston Children's Hospital
Layout table for additonal information
Responsible Party: Wanda Phipatanakul, Professor of Pediatrics, Boston Children's Hospital Identifier: NCT03694158    
Other Study ID Numbers: P00029072
U01AI143514 ( U.S. NIH Grant/Contract )
First Posted: October 3, 2018    Key Record Dates
Last Update Posted: May 30, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases